DA
AZN icon

Dillon & Associates’s AstraZeneca AZN Stock Holding History

Dillon & Associates’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.88M Buy
15,165
+891
+6% +$168K 0.35% 38
2026
Q1 		$2.81M Buy
14,274
+1,292
+10% +$249K 0.39% 41
2025
Q4 		$2.39M Buy
12,982
+371
+3% +$65.1K 0.31% 41
2025
Q3 		$1.94M Buy
12,611
+13
+0.1% +$1.97K 0.25% 43
2025
Q2 		$1.76M Buy
12,598
+507
+4% +$71.1K 0.24% 45
2025
Q1 		$1.79M Sell
12,091
-3,045
-20% -$441K 0.27% 45
2024
Q4 		$2M Sell
15,136
-1,289
-8% -$180K 0.28% 45
2024
Q3 		$2.56M Buy
16,425
+3,506
+27% +$566K 0.36% 41
2024
Q2 		$2.02M Buy
12,919
+875
+7% +$132K 0.29% 46
2024
Q1 		$1.64M Buy
12,044
+423
+4% +$56K 0.26% 48
2023
Q4 		$1.56M Buy
11,621
+443
+4% +$57.6K 0.28% 49
2023
Q3 		$1.52M Buy
11,178
+737
+7% +$101K 0.29% 48
2023
Q2 		$1.5M Buy
10,441
+1,344
+15% +$198K 0.28% 51
2023
Q1 		$1.25M Buy
9,097
+923
+11% +$124K 0.25% 51
2022
Q4 		$1.11M Buy
8,174
+1,199
+17% +$150K 0.24% 52
2022
Q3 		$767K Buy
6,975
+1,651
+31% +$209K 0.18% 54
2022
Q2 		$703K Buy
5,324
+922
+21% +$121K 0.16% 53
2022
Q1 		$581K Buy
4,402
+1,069
+32% +$128K 0.11% 54
2021
Q4 		$387K Buy
+3,333
New +$392K 0.07% 59

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dillon & Associates's AZN Position: Q2 2026 in Review

Dillon & Associates increased its AstraZeneca (AZN) stake by 6.2% in Q2 2026, buying an estimated $168K and bringing the position to 15,165 shares worth $2.88M. The position accounts for 0.35% of the portfolio, ranked #38.

Dillon & Associates first reported a position in AZN in Q4 2021 and has held it in 19 quarters since. 1,504 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Dillon & Associates held 15,165 shares of AstraZeneca worth $2.88M as of Q2 2026.
  • Dillon & Associates bought 891 AstraZeneca shares in Q2 2026, an estimated $168K.
  • AstraZeneca made up 0.35% of Dillon & Associates's portfolio in Q2 2026, its #38 holding.
  • Dillon & Associates first reported a position in AstraZeneca in Q4 2021 and has held it in 19 quarters since.
  • 1,504 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Dillon & Associates's 13F filing for Q2 2026, filed 5 Aug 2026.